Lugano, 2 December 2019 - The ESMO Immuno-Oncology Congress 2019, (1) the platform in Europe devoted entirely to the development and use of the immunotherapies against cancer, will take place from 11-14 December in Geneva, Switzerland, and will attract around one thousand participants from all over the world.
The event provides a comprehensive overview of this fast-moving field, from recent advances to those in the pipeline and is addressed to basic, translational and clinical researchers, immunologists, oncology clinicians.
The Congress programme (2) features numerous thought-provoking sessions about hot topics in the field of immuno-oncology, such as:
- Artificial intelligence (AI) meets immune-oncology (Friday, 13 December at 14:30 CET) (3)
- Reducing costs by decreasing either dose or frequency of dosing (Saturday, 14 December at 11:00 CET) (4)
- Status of CAR T-cells for cancer - Keynote lecture by Carl H. June (Wednesday, 11 December at 13:00 CET) (5)
- Mechanisms of immunotherapy efficacy versus resistance - Keynote lecture by by Thomas Gajewski, (6) winner of the 2019 ESMO Award for Immuno-Oncology (7) (Thursday, 12 December at 14:20)
Updated results will be presented for the following studies:
- LBA1: Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
- LBA2: First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: safety, pharmacokinetics (PK) and immunogenicity in CASPIAN
- LBA3: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 Part 2 final analysis
- LBA4: Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced nonsquamous NSCLC in KEYNOTE-042
- LBA5: KRAS mutational status and efficacy in KEYNOTE-189: pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
Other key aspects will be dealt with and discussed by expert panellists, including:
- Integrate Tumour Mutational Burden into daily practice, the way toward standardization
- Use of steroids and corticosteroids in immunotherapy
- Immunotherapy as first-line treatment across a range of tumour types
- Combination therapy in solid tumours
ESMO welcomes members of the press interested in reporting on cancer. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card.
Media representatives are required to observe and abide by the ESMO Media Policy. (8)
To register as press, please fill out the media registration. (9)
ESMO Press Office firstname.lastname@example.org
Notes to Editors
Please make sure to use the official name of the meeting in your reports: ESMO Immuno-Oncology Congress 2019 Official Congress Hashtag: #ESMOImmuno19
1 ESMO Immuno-Oncology Congress 2019: https:/
2 Congress programme: https:/
3 Artificial intelligence (AI) meets immune-oncology: https:/
4 Reducing costs by decreasing either dose or frequency of dosing: https:/
5 Status of CAR T-cells for cancer: https:/
6 Mechanisms of immunotherapy efficacy versus resistance: https:/
7 2019 ESMO Award for Immuno-Oncology: https:/
8 ESMO Media Policy: https:/
9 Media registration: http://esmo.
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With more than 23,000 members representing oncology professionals from over 150 countries worldwide, ESMO is the society of reference for oncology education and information. ESMO is committed to offer the best care to people with cancer, through fostering integrated cancer care, supporting oncologists in their professional development, and advocating for sustainable cancer care worldwide. Visit http://www.